Hansen Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 68.5384 million yuan, a decrease of 31.80%

Hansen Pharmaceutical released its semi-annual report for 2025, with operating revenue of 509 million yuan, a year-on-year increase of 5.91%. The net profit attributable to the parent company was 68.5384 million yuan, a year-on-year decrease of 31.80%; the net profit excluding non-recurring gains and losses was 64.7695 million yuan, a year-on-year decrease of 31.72%. The basic earnings per share were 0.1362 yuan